Solid Tumor Clinical Trials in Dallas, Texas

17 studies are recruiting for solid tumor in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dabrafenib and/or Trametinib Rollover Study

   This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Mary Crowley Cancer Research, Dallas, Texas

   Locations

   34 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT03340506 on ClinicalTrials.gov

2. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ut Southwestern, Dallas, Texas

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

3. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #111, Dallas, Texas

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

4. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

5. Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

   This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary an…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   CBCC Global Research Site 006, Dallas, Texas

   Locations

   9 in total

   Run by

   Alyssum Therapeutics

   See if you can join NCT06234098 on ClinicalTrials.gov

6. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

   Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back …

   Stage

   Phase 1

   Ages

   0 to 17

   Site

   Call for Information (Investigational Site 0054), Dallas, Texas

   Locations

   16 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT02332668 on ClinicalTrials.gov

7. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Dallas, Dallas, Texas

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

8. Study of STP938 (Dencatistat) in Advanced Solid Tumours

   The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mary Crowley Cancer Research Center, Dallas, Texas

   Locations

   7 in total

   Run by

   Step Pharma, SAS

   See if you can join NCT06297525 on ClinicalTrials.gov

9. VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

   This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.

   Stage

   Phase 1

   Ages

   0 to 30

   Site

   The University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   7 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT04796012 on ClinicalTrials.gov

10. A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

    The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Texas Oncology, Dallas, Texas

    Locations

    19 in total

    Run by

    Teligene US

    See if you can join NCT06010342 on ClinicalTrials.gov

11. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT Southwestern, Dallas, Texas

    Locations

    19 in total

    Run by

    NiKang Therapeutics, Inc.

    See if you can join NCT06586957 on ClinicalTrials.gov

12. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology, Dallas, Texas

    Locations

    18 in total

    Run by

    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov

13. A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

    This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site-104, Dallas, Texas

    Locations

    17 in total

    Run by

    Biohaven Therapeutics Ltd.

    See if you can join NCT06384807 on ClinicalTrials.gov

14. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

    This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mary Crowley Cancer Research, Dallas, Texas

    Locations

    21 in total

    Run by

    I-Mab Biopharma US Limited

    See if you can join NCT04900818 on ClinicalTrials.gov

15. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mary Crowley Cancer Research, Dallas, Texas

    Locations

    9 in total

    Run by

    ImmVira Pharma Co. Ltd

    See if you can join NCT04370587 on ClinicalTrials.gov

16. Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

    This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mary Crowley Cancer Research Centers, Dallas, Texas

    Locations

    8 in total

    Run by

    Impact Therapeutics, Inc.

    See if you can join NCT05269316 on ClinicalTrials.gov

17. BP1001-A in Patients With Advanced or Recurrent Solid Tumors

    This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is es…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mary Crowley Cancer Research, Dallas, Texas

    Locations

    4 in total

    Run by

    Bio-Path Holdings, Inc.

    See if you can join NCT04196257 on ClinicalTrials.gov